Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q4 FY23 results · Jan–Mar 2023
Tatva Chintan Pharma Chem reported revenue from operations of ₹124.51 crore (up 26.4% from Q4 FY22) and net profit of ₹16.95 crore (down 3.2% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 124.51 | 98.53 | +26.4% | 120.61 | +3.2% |
| Other income | 0.84 | 0.35 | +138.7% | 1.52 | −44.4% |
| Total income | 125.36 | 98.89 | +26.8% | 122.13 | +2.6% |
| Profit before tax | 7.80 | 18.98 | −58.9% | 14.22 | −45.1% |
| Net profit for the period | 16.95 | 17.51 | −3.2% | 11.62 | +45.9% |
| EPS, basic (₹) | 7.65 | 7.90 | −3.2% | 5.24 | +46.0% |
| Net margin (%) | 13.6 | 17.8 | 9.6 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.41 | 101.88 | +17.2% | 113.54 | +5.2% |
| Other income | 0.78 | 1.19 | −34.1% | 1.07 | −27.0% |
| Total income | 120.19 | 103.07 | +16.6% | 114.61 | +4.9% |
| Profit before tax | 6.89 | 19.96 | −65.5% | 13.15 | −47.6% |
| Net profit for the period | 16.15 | 18.89 | −14.5% | 10.56 | +53.0% |
| EPS, basic (₹) | 7.29 | 8.52 | −14.4% | 4.76 | +53.2% |
| Net margin (%) | 13.5 | 18.5 | 9.3 |
Consolidated
- Filed with BSE
- 08 May 2023, 11:42 IST
- Board meeting
- 05 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 May 2023, 11:42 IST
- Board meeting
- 05 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE